Tyrosine phosphorylation-and epidermal growth factor-dependent regulation of the sodium-coupled amino acid transporter B0 in the human placental choriocarcinoma cell line JAR  by Torres-Zamorano, Viviana et al.
 .Biochimica et Biophysica Acta 1356 1997 258–270
Tyrosine phosphorylation-and epidermal growth factor-dependent
regulation of the sodium-coupled amino acid transporter B0 in the
human placental choriocarcinoma cell line JAR
Viviana Torres-Zamorano, Ramesh Kekuda, Frederick H. Leibach, Vadivel Ganapathy )
Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912-2100, USA
Received 4 December 1996; accepted 17 December 1996
Abstract
We have recently cloned an amino acid transporter from the human placental choriocarcinoma cell line JAR which, when
functionally expressed in HeLa cells, induces an amino acid transport activity with characteristics known to be associated
0 with the amino acid transport system B R. Kekuda, P.D. Prasad, Y.J. Fei, V. Torres-Zamorano, S. Sinha, T.L. Yang-Feng,
.F.H. Leibach, and V. Ganapathy, J. Biol. Chem. 271, 18657–18661, 1996 . The presence of the amino acid transport
0  0.system B ATB has however not been previously described in these cells by functional studies. In the present
investigation, we have obtained evidence for the existence of ATB0 in JAR cells and delineated the functional
characteristics of the transporter. The identifying characteristics include Naq-dependence and preference for neutral amino
acids. In addition, we have used the JAR cells as a model system to investigate the regulatory aspects of ATB0. Treatment
 . 0of the cells with the neuroprotective agent aurintricarboxylic acid ATA for 16 h leads to a significant increase in ATB
activity. This increase is associated with enhanced maximal velocity of the transporter and with increased steady state levels
of the transporter mRNA. The effect of ATA is blocked by the tyrosine kinase inhibitor genistein. ATA treatment results in
increased tyrosine phosphorylation of two major proteins, 180 kDa and 140 kDa in size. The 180 kDa protein is likely to be
 .the epidermal growth factor EGF receptor because exposure of the cells to EGF also leads to enhanced tyrosine
phosphorylation of a protein of similar molecular size. Furthermore, the effects of ATA on ATB0 activity and on ATB0
mRNA levels can be reproduced by EGF. Treatment of the cells with EGF for 24 h results in a significant increase in ATB0
activity and this effect is associated with an increase in the maximal velocity of the transporter and with an increase in the
steady state levels of the transporter mRNA. These data suggest that ATA influences ATB0 activity in JAR cells most likely
by activating the EGF receptor through tyrosine phosphorylation. It is concluded that the human placental choriocarcinoma
Abbreviations: ATA, aurintricarboxylic acid; EGF, epidermal growth factor; ATB0, amino acid transporter B0; GAPDH, glyceralde-
w xhyde 3-phosphate dehydrogenase; MeAIB, a-methylaminoisobutyric acid; BCH, 2-aminobicyclo- 2.2.1 heptane 2-carboxylic acid; kb,
 .kilo base pair s .
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cells functionally express the amino acid transport system B0 and that the expression of the system in these cells is
stimulated by EGF.q 1997 Elsevier Science B.V. All rights reserved.
Keywords: Amino acid transport; System B0; Tyrosine phosphorylation; Epidermal growth factor; Regulation of expression; mRNA
level; Choriocarcinoma cell; Placenta, human
1. Introduction
The amino acid transporter B0 is a Naq-dependent,
broad-scope, neutral amino acid transport system ex-
w x w xpressed in the intestinal 1,2 and renal 3,4 brush
border membranes. This system has also been shown
to be expressed in the human intestinal cell line
w xCaco-2 5 and in the bovine kidney cell line NBL-1
w x6 . A wide variety of zwitterionic amino acids, in-
 . cluding branched chain e.g. leucine , aromatic e.g.
.  .phenylalanine , short chain e.g. alanine and ami-
 .dated e.g. glutamine amino acids, are accepted as
substrates for System B0. Anionic amino acids,
cationic amino acids, and N-methylated amino acids
are excluded by the system. This transporter is differ-
entiated from the closely related transport system
B0,q, which accepts zwitterionic as well as cationic
w xamino acids as substrates 7 . Based upon the known
expression of system B0 in the intestine and the
kidney and the known preference of this system for
neutral amino acids, it has been proposed that the
inheritable amino acid transport defect Hartnup dis-
0 w xease may be associated with defective System B 8 .
This disease is characterized by impaired transport of
a variety of neutral amino acids in the intestine and
w xthe kidney 9 . Recent evidence indicates that the
expression of System B0 in Caco-2 cells is regulated
w xby protein kinase C 5 . In addition, Plakidou-Dy-
w xmock et al 10 have described a novel means of
control for System B0 expression in NBL-1 cells
which involves induction of the system by the pres-
ence of phenylalanine during amino acid starvation.
We have recently cloned and characterized an
amino acid transporter from the human placental
w xchoriocarcinoma cell line JAR 11 . When function-
ally expressed in HeLa cells, this transporter mediates
the Naq-dependent uptake of several zwitterionic
amino acids. These functional characteristics have led
to the identification of the cloned transporter as the
amino acid transporter B0. Interestingly, System B0
has not been described in the JAR cell line or in the
normal human placenta. In this paper, we provide
evidence for endogenous expression of System B0 in
JAR cells and, in addition, for regulation of its
expression by epidermal growth factor and tyrosine
phosphorylation.
2. Materials and methods
2.1. Materials
The human placental choriocarcinoma cell line
JAR was obtained from the American Type Culture
 .Collection Rockville, MD, USA . Culture media
 .RPMI 1640 , penicillin, streptomycin, and trypsin
were purchased from Mediatech Herndon, VA,
.USA . Fetal bovine serum, aurintricarboxylic acid
 1.ATA , prostaglandin E , apotransferrin, thyroxine,1
EGF, and amino acids were from Sigma St. Louis,
.MO, USA . Human recombinant insulin was from
 .Novo Nordisk Pharmaceuticals Princeton, NJ, USA .
Genistein was from Research Biochemicals Natick,
. w 3 x MA, USA . L- 2,3- H Alanine specific radioactivity,
. 50 Cirmmol was obtained from DuPont-NEN Bos-
. w 32 xton, MA, USA . a- P dCTP was from Amersham
 .Arlington Heights, IL, USA . Antiphosphotyrosine
 .antibody PY 20 was purchased from Transduction
 .Laboratories Lexington, KY, USA .
2.2. Culture and treatment of JAR cells
JAR cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum, penicillin
 .  .100 Urml , and streptomycin 100 mgrml .
Trypsin-released cells were seeded in 35 mm petri
dishes at a density of 1.5=106 cellsrdish and al-
lowed to grow for 24 h in RPMI 1640 medium
containing 10% fetal bovine serum. Following the 24
h subculture, the medium was replaced with a hor-
monally defined medium which did not contain fetal
bovine serum. The defined medium consisted of
 .RPMI 1640, supplemented with insulin 5 mgrml ,
 . apotransferrin 5 mgrml , prostaglandin E 2.5=1
y5 .  y12 .10 mgrml , and thyroxine 5=10 M . Treat-
ment with different agents including EGF was carried
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out for indicated time periods in the defined medium
prior to uptake measurements.
2.3. Uptake measurements
The culture medium from the dishes was removed
by aspiration and the cells were washed once with the
uptake buffer. One ml of uptake buffer containing
radiolabeled alanine was added to the cells and incu-
bated for 2 min. Uptake was terminated by aspirating
the uptake buffer from the dish and subsequently
washing the cells thrice with uptake buffer. The cells
were lysed with 1 ml of 1% SDS–0.2 N NaOH and
the lysate was transferred to counting vials for mea-
surement of radioactivity. The composition of the
 .uptake buffer was 25 mM HepesrTris pH 7.5 , 140
mM NaC1, 5.4 mM KC1, 1.8 mM CaCl , 0.8 mM2
MgSO , and 5 mM glucose. In some experiments, the4
composition of the uptake buffer was modified by
replacing 25 mM HepesrTris with 25 mM MesrTris
 .pH 5.5 . Alanine uptake that occurred in the absence
of Naq was subtracted from total uptake to calculate
Naq-dependent uptake. The Naq-free uptake buffer
was prepared by replacing NaC1 with choline chlo-
ride. In some experiments, a Cly-free uptake buffer
was used and its composition was 25 mM HepesrTris
 .pH 7.5 , 140 mM sodium gluconate, 5.4 mM potas-
sium gluconate, 1.8 mM calcium gluconate, 0.8 mM
Mg SO , and 5 mM glucose.4
( )q2.4. Isolation of Poly A RNA and Northern blot
analysis
 .qPoly A RNA was isolated from JAR cells using
FastTrack mRNA isolation Kit Invitrogen, San
.Diego, CA, USA . Northern blot hybridization was
carried out under high stringency conditions using
32P-labeled human ATB0 cDNA as the probe. The
same membrane blot was used for probing with either
32P-labeled human glyceraldehyde 3-phosphate dehy-
 . 32drogenase GAPDH cDNA or P-labeled mouse
b-actin cDNA as an internal control for RNA loading
and transfer efficiency. Quantification of transcript
signals in autoradiograms was done with a Hewlett
 . 0Packard densitometer Scan Jet II CX . The ATB
cDNA probe was a 1.4 kb fragment obtained by
digestion with XhoI and BamHI from the human
0 w xATB clone 11 . The GAPDH cDNA probe was a
0.78 kb fragment obtained from a human GAPDH
clone American Type Culture Collection, Rockville,
.MD, USA by digestion with Pst I and XbaI. The
b-actin cDNA probe was a 1.2 kb fragment obtained
from a mouse b-actin clone by digestion with PstI.
The b-actin clone was kindly provided by Dr. V.B.
Mahesh, Department of Physiology and Endocrinol-
ogy, Medical College of Georgia. The cDNA probes
w 32 xwere radiolabeled with a- P dCTP by random
priming using ready-to-go oligolabeling kit from
 .Pharmacia Biotech Piscataway, NJ, USA .
2.5. Immunoblot analysis of phosphotyrosine-
containing proteins
JAR cells were cultured for 24 h in the presence of
fetal bovine serum and for another 24 h in the
hormonally defined medium. Cells were then treated
 .with either ATA 150 mM for different time periods
 .  .0–6 h or EGF 100 ngrml for 5 min. Control cells
were treated in a similar way in the absence of these
reagents. Following the treatment, the medium was
removed and the cells were lysed with 400 ml of
SDS-PAGE sample buffer 62.5 mM TrisrHCl, pH
.6.8, 50 mM dithiothreitol, 2.5% SDS, 10% glycerol
containing 1 mM orthovanadate. The samples were
boiled for 5 min at 1008C and centrifuged. The
supernatant was used for SDS-PAGE. The size-frac-
tionated proteins were transferred onto a nitrocellu-
lose membrane. The blots were blocked with 3% fetal
bovine serum, 1% nonfat dry milk, and 0.5% Tween-
20. The blots were probed with anti-phosphotyrosine
 .antibody 1 mgrml and the immunoreactive proteins
were detected using the Enhanced chemilumines-
cence Western blotting detection kit from Amersham
 .Arlington Heights, IL, USA .
2.6. Data analysis
Uptake experiments were done in duplicate or
triplicate and each experiment was repeated two or
three times. Kinetic analysis was done using commer-
cially available computer programs Fig. P, version
6.0 or Sigma Plot. Northern blot analysis was done
twice in the case of ATA and thrice in the case of
EGF. Data are presented as means"S.E.
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3. Results and discussion
3.1. E˝idence for expression of amino acid transport
system B0 in JAR cells
Alanine has been shown to be an excellent sub-
strate for the amino acid transport system B0 that is
expressed in the human colon carcinoma cell line
w xCaco-2 5 , the bovine renal epithelial cell line NBL-1
w x w x6 , and the rabbit intestine 12 . Therefore, we used
this amino acid as a test substrate to determine
whether the B0 system is expressed in the human
placental choriocarcinoma cell line JAR. Fig. 1 de-
scribes the uptake of alanine in JAR cells in the
presence and in the absence of Naq. Uptake of
alanine was rapid from a NaCl-containing uptake
medium. In contrast, the uptake was reduced markedly
when NaCl in the uptake medium was replaced by
choline chloride. When the concentration of alanine
was 2.5 nM, uptake in the presence of Naq was at
least 10-fold greater than in the absence of Naq at all
time periods. Similar results were obtained when the
concentration of alanine was 50 mM instead of 2.5
nM. Thus, the uptake of alanine in JAR cells occurs
predominantly via a Naq-dependent amino acid trans-
port system.
Alanine is a potential substrate for at least three
Naq-dependent amino acid transport systems known
to be expressed in epithelial cells. These three sys-
tems are A, ASC, and B0. These systems can how-
ever be differentiated from their substrate specificity.
We characterized the substrate specificity of the
transport system responsible for alanine uptake in
JAR cells by studying the ability of various amino
w3 xacids to inhibit the uptake of H alanine. Fig. 2
describes the dose-response relationship for the inhi-
w3 xbition of H alanine uptake by selected amino acids
and Table 1 gives the IC values the concentration50
of the amino acid which causes 50% inhibition of
w3 x .H alanine uptake for those amino acids which
showed marked inhibition within the concentration
 .range studied 1 mM–10 mM . Even at a concentra-
tion as high as 10 mM, the System A-specific sub-
strate MeAIB caused only about 10% inhibition of
alanine uptake. The bicyclic amino acid BCH was
similarly less effective, causing approx. 25% inhibi-
tion at 10 mM. The cationic amino acids arginine and
lysine which are substrates for the Naq-dependent
system B0,q known to be expressed in certain cell
w xtypes 7 were also found to be not effective as
inhibitors of alanine uptake in JAR cells. In contrast,
the short-chain neutral amino acids alanine, serine,
q  .Fig. 1. Time-course of alanine uptake in the presence and absence of Na . Uptake of alanine at 2.5 nM or at 50 mM inset in confluent
 .  .cultures of JAR cells was measured from uptake medium containing NaCl v or choline chloride ‘ . Composition of the uptake
 .  .medium was in mM 25 HepesrTris pH 7.5 , 5.4 KCl, 1.8 CaCl , 0.8 MgSO , 5 glucose and 140 NaCl or choline chloride.2 4
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Fig. 2. Substrate specificity of alanine transport process. Uptake
w3 x  .of H alanine 2.5 nM in confluent cultures of JAR cells was
 .measured with a 2-min incubation from uptake medium pH 7.5
containing NaCl in the presence or absence of indicated unla-
beled amino acids. Concentration range for unlabeled amino
acids were 1 mM–10 mM. Results are given as percent of control
 .uptake 0.20"0.02 pmolrmg of proteinr2 min measured in the
 .  .absence of unlabeled amino acids. Key: A Alanine ‘ , serine
 .  .  .  .  .v , cysteine I , threonine B , BCH e , and MeAIB ’ ;
 .  .  .  .  .B Glutamine ‘ , asparagine v , lysine I , arginine B ,
 .  .  .glycine ’ , leucine ^ , and phenylalanine e .
cysteine, and threonine as well as the amidated amino
acids glutamine and asparagine were highly potent in
interacting with the alanine-transporting system in
JAR cells. The IC values for these amino acids for50
w3 xthe inhibition of H alanine uptake ranged between
 . 144 mM for glutamine and 295 mM for as-
.paragine . Other neutral amino acids such as glycine,
 .leucine a branched-chain amino acid , and phenyl-
 .alanine an aromatic amino acid also inhibited
w3 xH alanine uptake, though with much lesser potency
than seen in the cases of short-chain and amidated
amino acids. These substrate specificity studies effec-
tively rule out participation of System A and System
B0,q in the observed uptake of alanine in JAR cells.
The inhibition of alanine uptake by glycine and by
 .leucine was competitive Fig. 3A . In this experi-
ment, alanine uptake was measured over a concentra-
tion range of 25–750 mM and, when present, the
concentrations of glycine and leucine were 5 mM
each. In the absence of glycine and leucine, the
values for K and V for alanine uptake weret max
174"6 mM and 11.2"0.2 nmolrmg of proteinr2
min. The corresponding values were 461"20 mM
and 10.3"0.3 nmolrmg of proteinr2 min in the
presence of glycine and 330"10 mM and 9.6"0.2
nmolrmg of proteinr2 min in the presence of leucine.
There are conflicting data in the literature with regard
to the kinetic nature of glycine-induced inhibition of
alanine uptake via System B0. In bovine renal epithe-
lial cell line NBL-1, the inhibition is noncompetitive
w x6 whereas in human intestinal cell line Caco-2, the
w xinhibition is competitive 5 . Therefore, we verified
the kinetic nature of glycine-induced inhibition of
 .alanine uptake in JAR cells by Dixon plot Fig. 3B .
Again, the inhibition was competitive. The K valuei
 .for glycine calculated from this experiment 3.5 mM
closely resembled the K value calculated from thei
Table 1
Relative potencies of various amino acids for the inhibition of
w3 xH alanine uptake in JAR cells
 .Amino acid IC value mM50
Glutamine 144"1
Threonine 158"4
Cysteine 192"2
Alanine 238"2
Serine 242"6
Asparagine 295"9
Glycine 2 790"218
Leucine 2 869"380
Phenylalanine 16 890"1166
The IC values were calculated from the data given in Fig. 2.50
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 .Fig. 3. Kinetics of inhibition of alanine uptake by leucine A and
 .  .by glycine A and B . A Uptake of alanine was measured in
confluent cultures of JAR cells over a alanine concentration
range of 25–750 mM and with a 2-min incubation from uptake
medium containing NaCl. Uptake of alanine measured in the
absence of Naq was subtracted from total uptake to calculate
Naq-dependent uptake which was used in data analysis. Alanine
 .uptake was measured in the absence v or presence of 5mM
 .  .glycine I or 5 mM leucine ’ . Results are given as Eadie-
Hofstee plots. Key: V, alanine uptake rate in nmolrmg of
 .proteinr2 min; s, alanine concentration in mM. B Uptake of
alanine was measured with a 2-min incubation at three concentra-
 .  .  .tions: 25 mM v , 75 mM B , and 150 mM ’ . Concentra-
tion of glycine was varied between 1 and 10 mM. Only Naq-de-
pendent alanine uptake was used in data analysis. Results are
given as Dixon plots. Key: V, alanine uptake rate in nmolrmg of
proteinr2 min.
 .IC data 2.8"0.2 mM . Apparently, the kinetics of50
interaction of glycine with System B0 are different
between the bovine cells and the human cells.
System ASC and System B0 exhibit significant
overlap in substrate specificity. System B0 that is
expressed in Caco-2 cells shows high affinity towards
short-chain neutral amino acids and amidated amino
w xacids 5 . The substrate specificity of the alanine
transporting system in JAR cells is markedly similar
to that described for System B0 in Caco-2 cells.
However, System ASC can also transport the ami-
dated amino acids glutamine and asparagine, in addi-
tion to the short-chain neutral amino acids alanine,
w xserine, cysteine, and threonine 13 . Even though the
ASC system cloned from human brain designated as
.ASCT 1 has been shown not to interact with glu-
w xtamine and asparagine 14,15 , a more recently cloned
ASC system from mouse testes designated as ASCT
.2 has been shown to transport glutamine and as-
w xparagine 16 . Therefore, additional studies were
needed to determine whether the uptake of alanine in
JAR cells is mediated by System B0 or by System
ASC. A unique characteristic of the ASC system is
that even though it does not exhibit measurable affin-
ity for the acidic amino acids aspartate, glutamate,
and cysteate at pH 7.5, its affinity for these amino
w xacids increases markedly at acidic pH 17 . This
characteristic has recently been demonstrated un-
w3 xFig. 4. Influence of acidic amino acids on H alanine uptake at
w3 x  .pH 7.5 and 5.5. Uptake of H alanine 2.5 nM in confluent
cultures of JAR cells was measured with a 2-min incubation from
 .uptake medium pH 7.5 or pH 5.5 containing NaCl in the
presence or absence of 5 mM acidic amino acids. Results are
given as percent of control uptake measured at respective pH
values in the absence of acidic acids 0.20"0.01 pmolrmg of
proteinr2 min at pH 7.5 and 0.12"0.01 pmolrmg of proteinr2
.min at pH 5.5 .
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equivocally for the ASC systems cloned from human
 . w x  .brain ASCT 1 18 and from mouse testes ASCT 2
w x16 . Therefore, we investigated the interaction of
acidic amino acids with alanine-transporting system
 .in JAR cells at two different pH, 7.5 and 5.5 Fig. 4 .
At both pH, the acidic amino acids cysteate, aspar-
tate, and glutamate failed to cause appreciable inhibi-
tion of alanine uptake in JAR cells. The maximal
inhibition observed at pH 5.5 with these amino acids
at a concentration of 5 mM was 25–30%. In contrast,
the uptake of alanine mediated by the cloned human
ASC system was completely inhibited by these amino
w xacids under comparable experimental conditions 18 .
These data demonstrate convincingly that alanine
uptake in JAR cells in mediated predominantly by
System B0. It is not clear whether the small inhibition
caused by acidic amino acids at pH 5.5 is due to
participation of system ASC to a small extent in
alanine uptake in JAR cells because system B0 may
itself have the ability to interact with acidic amino
acids at pH 5.5 to some extent, though not as promi-
nently as System ASC. However, the possible contri-
bution of System ASC to alanine uptake in JAR cells
cannot be entirely ruled out at this time. But, if this
system exists in JAR cells, its contribution to alanine
uptake is not expected to be greater than 25–30% at
the maximum.
Since alanine uptake in JAR cells occurs primarily
via System B0, we were able to study the dependence
of System B0 activity on Naq. Alanine uptake in
these cells was found to be stimulated by increasing
q concentrations of Na in a hyperbolic manner data
. qnot shown , indicating a Na ralanine coupling ratio
of 1. The K for Naq, i.e., the concentration of0.5
Naq necessary to stimulate alanine uptake to half-
maximal level, was 10.2"0.3 mM. Anions such as
y 0 Cl had no role in System B activity data not
.shown .
3.2. Role of tyrosine phosphorylation in the regula-
tion of system B0 acti˝ity in JAR cells
The successful isolation of the System B0 cDNA
clone from a cDNA library derived from JAR cell
w xmRNA 11 indicates that this system is expressed in
these cells. But, there has been no previous report
describing the existence of System B0 in these cells
by functional studies. The present study represents
the first evidence for functional expression of this
amino acid transport system in JAR cells. Very little
is known at present on the regulatory aspects of
System B0. Since the uptake of alanine in JAR cells
is mediated primarily by this system, this cell line
provides an excellent experimental model to investi-
gate the regulation of System B0.
ATA has been shown to be a very useful agent to
study the role of multiple signalling pathways involv-
w xing tyrosine phosphorylation in cell function 19 .
ATA is a neuroprotective agent which can prevent
cell death induced by deprivation of serum and NGF
w xin PC12 cells 20 , and also protect hippocampal
neurons from NMDAy and ischemia-induced death
w x21 . This compound induces tyrosine phosphoryla-
tion of several proteins which lie in prominent sig-
w xnalling pathways 19 . Therefore, we chose this com-
pound in our initial studies to determine whether
tyrosine phosphorylation plays any role in the regula-
tion of System B0 in JAR cells.
When confluent cultures of JAR cells were treated
 .without or with ATA 150 mM at 378C for various
 .time periods 1–16 h and then the cells were used
for measurement of alanine uptake, it was found that
ATA caused a significant stimulation of alanine up-
 .take Fig. 5A . The stimulation was not significant
when the treatment time was 1 h, but the stimulation
became highly significant when the treatment time
was 2 h or greater. The increase in alanine uptake
was about 30% when the treatment time was 16 h.
Fig. 5B describes the influence of ATA treatment on
the kinetic parameters of alanine uptake. Uptake was
measured with a 2-min incubation in control cells and
 .in cells treated with ATA 150 mM, 16 h treatment .
The range of alanine concentration used in this exper-
iment was 25–750 mM. The Eadie-Hofstee plot of
the uptake data in control cells gave a straight line
 2 .r s0.99 , indicating that there was only a single
transport system kinetically discernable which was
responsible for alanine uptake in JAR cells. The
Michaelis-Menten constant, K , for the system wast
239"5 mM and the maximal velocity, V , wasmax
16.1"0.2 nmolrmg of proteinr2 min. Kinetic anal-
ysis of alanine uptake in ATA-treated cells revealed
that the K value remained almost the same 271"2t
.mM as in control cells but the V increased signifi-max
 .cantly 22.0"0.1 nmolrmg of proteinr2 min .
To determine whether the ATA-induced stimula-
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 .Fig. 5. Stimulation of alanine uptake by ATA. A Confluent
cultures of JAR cells were treated with or without ATA 150
.mM for indicated time periods at 378C, following which uptake
w3 x  .of H alanine 2.5 nM was measured with a 2-min incubation
from uptake medium containing NaCl. Results are given as
percent stimulation compared to corresponding control uptake
measured in cells treated similarly in the absence of ATA.
Control uptake did not vary significantly among cultures treated
in the absence of ATA for indicated time periods 0.18"0.01
.  .pmolrmg of proteinr2 min . B Confluent cultures of JAR cells
 .  .  .were treated with v or without ‘ ATA 150 mM for 16 h at
378C. Uptake of alanine was measured in these cells over a
alanine concentration range of 25–750 mM and with a 2-min
incubation from uptake medium containing NaCl. Uptake of
alanine measured in the absence of Naq was subtracted from
total uptake to calculate Naq-dependent uptake which was used
in data analysis. Results are given as Eadie-Hofstee plots. Key: v,
alanine uptake rate in nmolrmg of proteinr2 min; s, alanine
concentration in mM.
tion of alanine uptake was due to ATA-induced
tyrosine phosphorylation of specific cellular proteins,
we studied the influence of genistein, an inhibitor of
several classes of tyrosine kinases, on the ATA effect
 .on alanine uptake Fig. 6 . Genistein was found to
block completely the stimulatory effect of ATA.
The increase in the V of the transport systemmax
and the requirement of long periods of treatment for
maximal effect suggested that the ATA-induced stim-
ulation of alanine uptake might involve increased
synthesis of the transport protein in response to ATA
treatment. Since alanine uptake in these cells occurs
primarily via the amino acid transport system B0, we
determined the steady state levels of B0 mRNA in
control and in ATA-treated cells Fig. 7; lanes 1 and
.3 respectively . The GAPDH mRNA levels were
used as internal control to normalize for RNA load-
ing and transfer efficiency during Northern blot hy-
bridization. In control cells as well as in ATA-treated
cells, the ATB0 cDNA identified a 2.9 kb mRNA
transcript and the GAPDH cDNA identified a 1.4 kb
mRNA transcript. The arbitrary B0 mRNArGAPDH
mRNA ratio for control cells was 0.47 and this value
increased to 0.76 for ATA-treated cells. This repre-
sents a 60% increase in the steady state levels of B0
mRNA as a result of ATA treatment. This increase
Fig. 6. Influence of genistein on ATA-induced stimulation of
w3 xH alanine uptake. Confluent cultures of JAR cells were treated
 .  .  .with or without control ATA 150 mM , genistein 60 mM or
 .  .ATA 150 mM plus genistein 60 mM for 16 h at 378C. Uptake
w3 x  .of H alanine 2.5 nM was measured at pH 7.5 with a 2-min
incubation from uptake medium containing NaCl. Results are
given as percent of uptake measured in control cells 0.21"0.01
.pmolrmg of proteinr2 min .
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Fig. 7. Influence of ATA and genistein on steady state levels of
ATB0 mRNA and GAPDH mRNA. Confluent cultures were
 .  .  .treated without lane 1 or with genistein 60 mM lane 2 , ATA
 .  .  .  .150 mM lane 3 or genistein 60 mM plus ATA 150 mM
 .  .qlane 4 . Poly A RNA was prepared from the cells, size-frac-
tionated, and probed with ATB0 cDNA or GAPDH cDNA by
sequential hybridization.
was reproducible in a second experiment in which
b-actin mRNA levels were used as internal control
 .data not shown . The increase in this experiment was
57%. Since cotreatment of the cells with ATA and
genistein was found to abolish the stimulatory effect
of ATA on alanine uptake, we also investigated
whether genistein could block the ATA-induced in-
crease in B0 mRNA levels. The steady state levels of
B0 mRNA and GAPDH mRNA were quantified in
cells treated either with genistein alone or with genis-
 .tein plus ATA Fig. 7; lanes 2 and 4 respectively .
The arbitrary B0 mRNArGAPDH mRNA ratio for
genistein-treated cells was 0.38. The corresponding
value for cells treated with ATA plus genistein was
0.37. These data show that genistein was able to
block the stimulatory effect of ATA on B0 mRNA
levels. Genistein treatment itself was found to de-
crease the B0 mRNArGAPDH mRNA ratio by about
20% compared to control cells. This agreed well with
a small decrease observed in alanine uptake in genis-
 .tein-treated cells compared to control cells Fig. 6 .
The biological actions of ATA are cell type-
specific. ATA protects PC12 cells from cell death,
but it does not prevent NIH3T3 cells from similar
w xcell death 19 . Interestingly, ATA is able to induce
tyrosine phosphorylation of several proteins in cell
signalling pathways in PC12 cells, but it has no effect
w xon tyrosine phosphorylation in NIH3T3 cells 19 . It
appears that the ability of ATA to induce tyrosine
phosphorylation is closely linked to its biological
effects and that ATA is not able to influence tyrosine
Fig. 8. Influence of ATA and EGF on tyrosine phosphorylation of cellular proteins in JAR cells. Confluent cultures of JAR cells were
 .  .  .  .treated without or with ATA 150 mM for indicated time periods left panel or with EGF 50 ngrml for 5 min right panel . Proteins in
 .cell lysates were separated by SDS-PAGE and then immunoblotted using anti-phosphotyrosine antibody PY 20 . Immunoreactive
proteins were detected by using commercially available Enhanced Chemiluminescence Western blotting detection kit. Proteins in the cell
 .lysate of A431 cells stimulated with 100 ngrml EGF for 5 min were run in parallel lane 1 in the left panel . Lane 2 in the left panel
contains mol wt. marker proteins. Exposure time for left panel was much longer than for right panel.
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phosphorylation in all cell types. These observations
suggest that ATA may initiate its effects by interact-
ing with a specific cellular protein which might be
expressed in a cell type-specific manner. Since ATA
induces alanine uptake activity and increases steady
state levels of B0 mRNA in JAR cells, we investi-
gated the influence of ATA on tyrosine phosphoryla-
tion in these cells. JAR cells were treated with ATA
 .for different time periods 0–6 h and phospho-
tyrosine-containing proteins in cell lysates were de-
tected by immunoblotting using a monoclonal anti-
body specific for phosphotyrosine residues. As shown
in Fig. 8, left panel, treatment of the cells with ATA
increased tyrosine phosphorylation of specific pro-
teins in a treatment time-dependent manner. At least
two proteins were clearly identified. A protein of 180
kDa exhibited markedly increased phosphotyrosine
content as a result of ATA treatment. This increase
was noticeable at 1 h of treatment, reached the maxi-
mum at 2 h, but declined at longer periods of incuba-
tion. The second protein had a molecular mass of 140
kDa and its phosphotyrosine content was found to
increase starting at 1 h of treatment with ATA.
However, unlike in the case of the 180 kDa protein,
the increase in the phosphotyrosine content of the
140 kDa protein persisted even after 2 h of treatment
with ATA.
In PC12 cells, ATA could stimulate most of major
signal transduction pathways which are influenced by
w xthe growth factors NGF and EGF 19 . This sug-
gested that the 180 kDa protein whose phospho-
tyrosine content was increased following ATA treat-
ment in JAR cells may be the EGF receptor. The
lysate of A431 cells a human epidermoid carcinoma
.cell line which had been exposed to EGF was run in
parallel with the JAR cell lysates to compare the
mobility the EGF receptor of the A431 cells with that
of the 180 kDa protein in JAR cells Fig. 8, left
.panel . A431 cells express abundant EGF receptor
and tyrosine phosphorylation of the receptor in-
creases dramatically when the cells are stimulated
with EGF. As shown in Fig. 8, the EGF-stimulated
A431 cell lysate contained a 180 kDa phospho-
tyrosine-containing protein. These data suggested that
ATA possibly leads to activation of the JAR cell
EGF receptor by increasing tyrosine phosphorylation
of the receptor. The identity of the 140 kDa protein
however remains unknown.
3.3. Role of EGF on system B0 acti˝ity in JAR cells
If the 180 kDa protein whose phosphotyrosine
content was increased following ATA treatment is
indeed the EGF receptor, we thought that treatment
of the JAR cells with EGF could reproduce the
effects of ATA on the alanine uptake and on the
steady state levels of B0 mRNA. To probe this
possibility, we first investigated the effect of EGF on
tyrosine phosphorylation in JAR cells for comparison
 .with the ATA effect Fig. 8, right panel . Treatment
 .of the cells with EGF 100 ngrml for 5 min resulted
in a robust increase in the phosphotyrosine content of
a 180 kDA protein which is most likely the EGF
receptor. These data provide evidence for the pres-
ence of EGF receptor in JAR cells and suggest that
the effects of ATA on system B0 mRNA and activity
in these cells may indeed be mediated by the activa-
tion of the EGF receptor.
These results led us to investigate the influence of
EGF on System B0 activity in JAR cells. Fig. 9A
describes the effect of treatment time with EGF on
alanine uptake. Treatment of the cells with EGF 50
.ngrml increased the uptake of alanine gradually as
the duration of treatment increased over a period of
1–24 h. The maximal increase observed was 20–25%.
Kinetic analyses of alanine uptake, performed over
the alanine concentration range of 25–750 mM, in
control and in EGF-treated EGF concentration, 50
.ngrml; treatment time, 24 h cells are described as
Eadie-Hofstee plots in Fig. 9B. For control cells, K t
for the uptake process was 216"6 mM and Vmax
was 14.7"0.2 nmolrmg of proteinr2 min. The
corresponding values for EGF-treated cells were 241
"7 mM and 18.7"0.4 nmolrmg of proteinr2 min.
Thus, the EGF-induced stimulation of alanine uptake
was primarily due to an increase in V . The affinitymax
of the uptake process for alanine was not signifi-
cantly altered. These results are similar to those
obtained with ATA.
To demonstrate unequivocally that the EGF-in-
duced increase in alanine uptake occurred via System
B0 rather than via system ASC, we studied alanine
uptake in control and EGF-treated cells at pH 7.5 and
5.5 in the presence and in the absence of 5 mM acidic
 .amino acids glutamate, aspartate, and cysteate . Ala-
nine uptake occurring via System ASC should be
completely inhibitable at pH 5.5 by the acidic amino
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 .Fig. 9. Stimulation of alanine uptake by EGF. A Confluent
cultures of JAR cells were treated with or without EGF 50
.ngrml for indicated time periods at 378C, following which
w3 x  .uptake of H alanine 2.5 nM was measured with a 2-min
incubation from uptake medium containing NaCl. Results are
given as percent stimulation compared to corresponding control
uptake measured in cells treated similarly in the absence of EGF.
Control uptake did not vary significantly among cultures treated
in the absence of EGF for indicated time periods 0.18"0.01
.  .pmolrmg of proteinr2 min . B Confluent cultures of JAR cells
 .  .  .were treated with v or without ‘ EGF 50 ngrml for 24 h
at 378C. Uptake of alanine was measured in these cells over a
alanine concentration range of 25–750 mM and with a 2-min
incubation from uptake medium containing NaCl. Uptake of
alanine measured in the absence of Naq was subtracted from
total uptake to calculate Naq-dependent uptake which was used
in data analysis. Results are given as Eadie-Hofstee plots. Key: v,
alanine uptake rate in nmolrmg of proteinr2 min; s, alanine
concentration in mM.
Table 2
w3 xH Alanine uptake in control and EGF-treated cells in the
presence and absence of acidic amino acids
3Acidic amino w xH Alanine uptake
acid Control EGF
 .  .pmolrmg per 2 min % stimulation
pH 7.5
None 0.392"0.007 0.487"0.002 24
Glutamate 0.348"0.001 0.423"0.007 22
Aspartate 0.360"0.005 0.431"0.006 20
Cysteate 0.366"0.004 0.435"0.016 19
pH 5.5
None 0.198"0.002 0.241"0.002 22
Glutamate 0.141"0.004 0.171"0.002 21
Asparate 0.174"0.003 0.218"0.001 25
Cysteate 0.128"0.001 0.162"0.001 27
 .The JAR cells were treated with or without EGF 50 ngrml for
w3 x 24 h at 378C. Following the treatment, uptake of H alanine 5
.nM was measured with a 2-min incubation either at pH 7.5 or at
pH 5.5 in the presence and in the absence of 5 mM acidic amino
 .acids. Values are mean"S.E. ns3
acids. The results are given in Table 2. EGF was
found to stimulate alanine uptake by about 20–25%
at pH 7.5 in the absence as well as in the presence of
the acidic amino acids. The EGF-induced stimulation
remained the same even when the uptake was mea-
sured at pH 5.5 in the presence or in the absence of
the acidic amino acids. These data clearly show that
the stimulation of System B0 activity was responsible
for the observed EGF-induced increase in alanine
uptake in JAR cells.
We then determined the influence of EGF on
steady state levels of B0 mRNA in these cells. North-
ern blot hybridization with the ATB0 cDNA as the
probe detected a single 2.9 kb mRNA species in
 .control cells and in EGF-treated cells Fig. 10 . After
normalizing the data for variations in RNA loading
and transfer efficiency based upon the GAPDH
mRNA signals used as an internal control, EGF
treatment was found to increase the B0 mRNA levels
by 75% and 58% in two separate experiments. The
experiment was repeated for the third time, using
b-actin mRNA levels instead of GAPDH mRNA
levels as the internal control. The increase in the
steady state levels of B0 mRNA in response to EGF
 .treatment was again reproducible data not shown .
The increase in the third experiment was 59%.
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Fig. 10. Influence of EGF on steady state levels of ATB0 mRNA
and GAPDH mRNA. Confluent cultures of JAR cells were
 .  .  .treated without lane 1 or with lane 2 EGF 50 ngrml for 24 h
 .qa t 378C. Poly A RNA was prepared from the cells, size-frac-
tionated, and probed with ATB0 cDNA or GAPDH cDNA by
sequential hybridization.
The results of the present study provide evidence
.for the following: i the human placental choriocarci-
noma cell line JAR constitutively expresses the Naq-
dependent, broad-scope, amino acid transport System
B0 and this system mediates most of the Naq-depen-
.dent alanine uptake in this cell line, ii ATA, a
neuroprotective agent which is known to induce tyro-
sine phosphorylation in cell type-specific manner,
stimulates System B0 activity in JAR cells and this
stimulation is associated with increased tyrosine
phosphorylation of specific proteins and with in-
0 .creased steady state levels of B mRNA. iii EGF
stimulates System B0 activity in JAR cells and this
effect is associated with increased steady state levels
0 . 0of B mRNA, and iv ATA influences System B
activity by activating the EGF receptor through tyro-
sine phosphorylation and a common cellular sig-
nalling pathway is most likely involved in mediating
the observed effects of ATA and EGF. This is the
first demonstration of functional expression of Sys-
tem B0 in a human placental cell line. Interestingly,
there has been no report on the presence of B0
w x qactivity in normal human placenta 22,23 . Na -De-
pendent uptake of alanine in isolated placental brush
border and basal membrane vesicles is apparently
mediated by amino acid transport systems A and
ASC. System B0 is prominently expressed in epithe-
lial cells such as the intestinal and renal absorptive
w xcells 1–6 . The syncytiotrophoblast, which is the
absorptive cell in normal placenta, is also an epithe-
lial cell and therefore it is very likely that System B0
is functionally expressed in this cell. Northern blot
analysis of human placental mRNA using the JAR
cell B0 cDNA as the probe indicates the presence of
o w xB mRNA in this tissue 11 The functional charac-
teristics of System B0 in JAR cells described in this
study are very similar to those of System B0 present
w xin Caco-2 cells 5 . These characteristics include sub-
strate specificity, affinity for alanine, affinity for
Naq, and Naqralanine coupling ratio. Furthermore,
the JAR cell B0 cDNA identifies a single, prominent
2.9 kb mRNA species in JAR cells and in Caco-2
w xcells under high stringency conditions 11 . The pre-
sent study provides evidence for the first time for
functional expression of System B0 in a cell line of
non-intestinal and non-renal origin, showing that the
existence of this transport system in animal tissues is
more widespread than previously thought.
Regulation of System B0 has been demonstrated in
w xCaco-2 cells with phorbol esters 5 and in NBL-1
cells by phenylalanine under amino acid deprivation
w xconditions 10 . The present study describes for the
first time the regulation of System B0 by a hormone.
EGF activates System B0 in JAR cells and this effect
is most likely associated with increased synthesis of
the transporter protein. This is supported by the
requirement of relatively long periods of EGF treat-
ment to produce the stimulatory effect and by the
facts that the EGF-induced increase in System B0
activity is associated with an increase in the maximal
velocity of the transport process and in the steady
state levels of B0 mRNA. It is not known however
whether the increase in mRNA levels is due to
enhanced transcription rate or increased mRNA sta-
bility. We were unable to use the transcription in-
hibitor actinomycin D to investigate the possible role
of transcription in the observed effects of EGF be-
cause exposure of JAR cells to actinomycin D for
long periods of incubation as needed to observe the
EGF effect proved to be toxic to the cells. Cyclohex-
imide, an inhibitor of protein synthesis was also
found to be toxic to the cells under these conditions
and therefore could not be used to determine the
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participation of de novo synthesis of B0 protein in
the EGF-induced increase in B0 activity.
The results of the present study which demonstrate
stimulation of System B0 activity by EGF may have
relevance to modulation of amino acid transport across
the placenta. EGF receptors are abundantly expressed
in human placenta, primarily in the maternal-facing
brush border membrane of the syncytiotrophoblast
w x24,25 . EGF in the maternal circulation may function
in optimal maintenance of B0 activity in the placenta
by acting through its receptor in the placental brush
border membrane.
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